Coeptis gave Deverra around $570,000 in cash and 4,000,000 shares of its common stock for the immuno-oncology platform and two IND applications and two assets that are currently in Phase 1 trials
Coeptis licenses Deverra’s clinical stage assets. (Credit: CDC on Unsplash)
Biopharmaceutical company Coeptis Therapeutics has signed an exclusive license for an allogeneic immuno-oncology platform and clinical-stage assets from US-based Deverra Therapeutics.
Under the terms of the deal, Coeptis gave Deverra around $570,000 in cash and 4,000,000 shares of its common stock.
The deal is focused around Deverra’s proprietary allogeneic stem cell expansion and directed differentiation platform that generates multiple distinct immune effector cell types, with natural killer and monocyte/macrophages.
The transaction enables Coeptis to further extend its pipeline, potentially accelerating the development of new products.
According to the biopharmaceutical company, the addition of a patentable and scalable allogeneic immune cell manufacturing platform will complement its current SNAP-CAR and GEAR technologies.
Coeptis Therapeutics president and CEO Dave Mehalick said: “Finalising this transaction represents a pivotal transition of Coeptis into a clinical-stage company with novel, synergistic and differentiated cell therapy pipeline candidates.
“As we move forward, I am excited to work with Colleen Delaney, MD, a visionary scientist whose career has been dedicated to researching and advancing all aspects of cell therapy product development.
“A true leader in the field, Colleen’s experience and leadership will be invaluable as we progress our expanded pipeline towards our ultimate goal of bringing improved treatments to patients in need.”
In connection with the transaction, Coeptis gains exclusive rights to two Investigational New Drug (IND) applications and two assets that are currently undergoing Phase 1 clinical trials.
Additionally, the biopharmaceutical firm is expanding its current portfolio of cell therapy product candidates with the addition of a distinctly scalable allogeneic cellular immunotherapy platform.
The platform is said to generate and deliver off-the-shelf, affordable, on-demand cell therapies to a large patient population.
Along with the Phase 1 assets, this transaction gives Coeptis the tools it needs to start incorporating allogeneic technologies into its pipeline assets which are already in the clinical stage.
This will help to speed up the development of targeted novel products, possibly leading to the creation of allogeneic-engineered NK and MAC cell therapies, the company said.